A Pilot Study to Characterize the Bioavailability and Plasma Profile of Potato Polyphenols in Humans (PPT)

Primary objective is to determine the bioavailability of and characterize the kinetic profile of target polyphenol metabolites of potatoes over 6 hour postprandial period.

Secondary objective is to assess the influence of potatoes' bioavailability and kinetic profiles on markers of chronic diseases.

Study Overview

Detailed Description

The proposed study is a single-center, placebo-controlled, randomized, 2-arm, 2-sequence, crossover study that characterizes the bioavailability and kinetic profile of potatoes over 6-hour postprandial day (PPD).

A planned sample size of 12 will be enrolled into the study. This study will require one initial screening visit, pre-study visit, and 2 PPDs. This study will take 3-6 weeks per subject to complete.

The trial will initiate with a screening visit, which will last for about 1-1.5 hours where the subjects' height, weight, waist circumference, fasting blood glucose, fasting hs-CRP (high sensitivity C-reactive protein) concentration, blood pressure and heart rate will be measured and a survey related to general eating, health and exercise habits will be completed.

If willing and eligible to participate, a 3-day food record (2 weekdays and 1 weekend) will be given at the screening visit and collected on the following pre-study Visit to assess subject's baseline dietary intake and pattern. Also, subjects will be instructed to follow a relatively low polyphenolic-diet at least 7 days prior to the first PPD and for the duration of the study. Prior to each PPD, a dinner meal will be provided the day before the PPD to control the second meal effect from food and beverage intake of the night before the PPD.

Subjects will arrive at the center in a fasting state for at least 10 hours, well hydrated and rested. Each PPD will require blood draws throughout the visit. After evaluation of subject's health status (via anthropometric, vital sign and blood glucose measurements and in-person interview), a registered nurse will place a catheter in subject's arm for the purpose of multiple blood sample collections and take the initial blood draw at fasting. A standard high carbohydrate and high fat test meal with either 200g white potato or 200g purple potato will be served. Thereafter, timers will be started and blood sample will be collected at 20, 40, 60, 120, 180, 240, 300, and 360 minutes for assessment in plasma bioavailability and kinetic profile of potato polyphenols and changes in inflammation markers and relative metabolic indices. The sequence of receiving the potato treatment at each visit will be randomly assigned based on computer generated sequences: white potato-purple potato or purple potato-white potato.

Premenopausal female subjects will be studied during the follicular phase of their menstrual cycle because food intake tends to be more stable during the follicular phase (days 1-13) than during the luteal phase (days 14-28) when the rise in progesterone levels decrease satiety and often resulting in increased intake. Both PPD visits will be placed at least 3 days apart as well.

Study Type

Interventional

Enrollment (Actual)

13

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Illinois
      • Chicago, Illinois, United States, 60616
        • Clinical Nutrition Research Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 41 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Premenopausal women with regular menstrual cycle
  • Aged between 20 to 45 years old
  • Body Mass Index (BMI) range from 25 to 35 kg/m2; exception BMI 23 to 35 kg/m2 for Asian population
  • Fasting blood glucose concentration < 110 mg/dL
  • Fasting hs-CRP >2 mg/dL to < 10 mg/dL
  • Weight stable: not gained or lost weight +/- 5 lbs in previous 3 months
  • Non-smokers
  • No clinical evidence of cardiovascular, metabolic, respiratory, renal, gastrointestinal or hepatic disease
  • Not taking any medications or dietary supplements that would interfere with outcomes of the study, i.e. lipid lowering medications, anti-inflammatory drugs, fish oil, probiotics, grape seed supplement, etc…If anti-inflammation and/or antibiotic medications/supplements are taken, subjects may qualify if go off these medications/supplements 30 days wash-out before entering the study.
  • Able to provide informed consent
  • Able to comply and perform the procedures requested by the protocol

Exclusion Criteria:

  • Men
  • Past smokers: abstinence for less than 2 years
  • Women who smoke
  • Women with known or suspected food intolerance, allergies or hypersensitivity to the study materials or closely related compound or any their stated ingredients.
  • Women known to have/diagnosed with diabetes mellitus
  • Women who have fasting blood glucose concentrations ≥110 mg/dL
  • Women who have uncontrolled blood pressure >140 mmHg/90 mmHg
  • Women with documented vascular disease, e.g., heart failure, myocardial infarction, stroke, angina, related surgeries.
  • Women with cancer other than non-melanoma skin cancer in previous 5 years.
  • Women who are taking medication or dietary supplements that may interfere with the outcomes of the study; e.g., antioxidant supplements, anti-inflammation, lipid lowering medication. Subjects may choose to go off dietary supplements (requires 30 days washout).
  • Women who are taking blood pressure lowering medication that may interfere the outcomes of the study; e.g. diuretics.
  • Women who have donated blood within 3 months of the screening visit and blood donors/participants for whom participation in this study will result in having donated more than 1500 milliliters of blood in the previous 12 months.
  • Women who are vegetarians or vegans
  • Substance (alcohol or drug) abuse within the last 2 years.
  • Excessive coffee and tea consumers (> 4 cups/day); berry and grape consumers (>2 cups/day)
  • Women who do excessive exercise regularly or athlete
  • Unstable weight: gained or lost weight +/- 5 lbs in previous 3 months
  • Women who are known to be pregnant or who are intending to become pregnant over the course of the study
  • Women who are lactating

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Purple Potato
Active Comparator
Purple Potato
Other Names:
  • Purple Potato
Placebo Comparator: White Potato
Placebo Comparator
Placebo Comparator
Other Names:
  • White Potato

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in plasma polyphenol metabolite concentrations over 6 hours after white or purple potato consumption with a high carbohydrate and high fat meal.
Time Frame: 6 hours
To assess the kinetic profile and bioavailability of potato polyphenols when consume with a meal
6 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in metabolic and inflammation markers over 6 hours after white or purple potato consumption with a high carbohydrate and high fat meal.
Time Frame: 6 hours
The influence of white or purple potato consumption on metabolic and inflammation markers
6 hours

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in oxidative stress markers over 6 hours after white or purple potato consumption with a high carbohydrate and high fat meal
Time Frame: 6 hours
The influence of white or purple potato consumption on oxidative stress markers
6 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Britt Burton-Freeman, Ph.D, MS, Illinois Institute of Technology

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2014

Primary Completion (Actual)

October 27, 2014

Study Completion (Actual)

November 11, 2014

Study Registration Dates

First Submitted

June 17, 2014

First Submitted That Met QC Criteria

June 17, 2014

First Posted (Estimate)

June 19, 2014

Study Record Updates

Last Update Posted (Actual)

January 28, 2021

Last Update Submitted That Met QC Criteria

January 26, 2021

Last Verified

January 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2014-033

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Premenopausal Women

Clinical Trials on Active Comparator

Subscribe